CompoAtlas

Pi pa qing fei yin

Food supplement declared in France, declaration No 2021-8-1124, decision dated 25 August 2021

Pi pa qing fei yin, from Calebasse, is a food supplement declared in France. Status: declared in France, may be marketed. Main ingredients: Rehmannia glutinosa 1.54 g per day, Paeonia lactiflora 1.38 g per day, Gardenia jasminoides 0.62 g per day, Morus alba 0.62 g per day, Phellodendron amurense 0.62 g per day. 1 point in its composition requires a check (prohibited substance, dose or novel food). 2 rules of use apply to its ingredients (limits and warnings).

Brand
not provided
Food business operator placing the product on the market
Calebasse
Status
Declared in France, may be marketed: the authorities did not object to the declaration (this is neither an authorisation nor a safety assessment)
Form
Powder
Daily dose
6 g
Not recommended (according to the manufacturer)
Breastfeeding women, Children (under 12), Young children (aged 1 to 3), Pregnant women, Infants (under 1 year), Taking diabetes medication, Prolonged use
Objectives stated by the manufacturer (these are not authorised claims)
Detox / Drainage

Declaration 312671, procedure Article 16. Compl'Alim, food supplement declarations (France), retrieved 15 November 2026.

Declared composition

Plants

PlantPartPreparationPer day
Rehmannia glutinosa (Gaertn.) DC.RacineExtrait sec aqueux1.54 g
Paeonia lactiflora Pall.RacineExtrait sec aqueux1.38 g
Gardenia jasminoides J. EllisFruitExtrait sec aqueux0.62 g
Morus alba L.TigeExtrait sec aqueux0.62 g
Phellodendron amurense Rupr.EcorceExtrait sec aqueux0.62 g
Coptis teeta Wall.RhizomeExtrait sec aqueux0.46 g
Eriobotrya japonica (Thunb.) Lindl.FeuilleExtrait sec aqueux0.46 g
Glycyrrhiza uralensis Fisch.RacineExtrait sec aqueux0.3 g

List from the declaration, administrative decision dated (Compl'Alim, food supplement declarations (France)).

Photograph the packaging

Label warnings

Consultez votre médecin ou votre pharmacien en cas d’usage concomitant de traitement contre le diabète. Ne pas utiliser plus de 6 semaines sans avis médical.

Regulatory points

This information reproduces the manufacturer's declaration to the administration (DGAL). It does not say whether the product is effective and does not replace advice from a doctor or pharmacist, particularly during pregnancy or when taking medication.

Official warnings (Health Canada)

Health Canada publishes warnings on these ingredients:

  • Glycyrrhiza uralensis Fisch.
    Read the warning, when it applies and the studies cited

    DEGLYCYRRHIZINATED LICORICE Buccal

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 October 2025

    Deglycyrrhizinated Licorice Oral

    Cautions and warnings

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Health Canada monograph dated 31 January 2025

    LICORICE

    Route of administration: Oral

    Cautions and warnings

    Condition of application: All products.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician before use if you are breastfeeding (Gardner and McGuffin 2013).

    Sources cited by Health Canada (1)
    • Gardner Z, McGuffin M. editors. 2013. American Herbal Products Association's Botanical Safety Handbook, 2nd edition. Boca Raton (FL): CRC Press.

    Condition of application: Cough relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if cough worsens or persists (for) more than 1 week (EMA 2012).

    Sources cited by Health Canada (1)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf

    Condition of application: Gastritis relief.

    Ask a health care practitioner/health care provider/health care professional/doctor/physician if symptoms persist or worsen.

    Contraindications

    Condition of application: All products.

    Do not use if you are pregnant (EMA 2012).

    Sources cited by Health Canada (2)
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • Gardner Z, McGuffin M. éditeurs. 2013. American Herbal Products Association's Botanical Safety Handbook, 2e édition. Boca Raton (FL): CRC Press.

    Do not use if you have hypokalemia, high blood pressure, or a kidney, liver or cardiovascular disorder (EMA 2012; Brinker 2010; ESCOP 2003; Bradley 1992).

    Sources cited by Health Canada (4)
    • Bradley PR, editor. British Herbal Compendium: A Handbook of Scientific Information on Widely Used Plant Drugs, Volume 1. Bournemouth (UK): British Herbal Medicine Association; 1992.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • EMA 2012. European Medicines Agency. Community Herbal Monograph on Glycyrrhiza glabra L. and/or Glycyrrhiza inflata Bat. and/or Glycyrrhiza uralensis Fisch., radix. London (UK): EMA Committee on Herbal Medicinal Products (HMPC), 22 May 2012. [Accessed 2024 January 6]. Available from: https://www.ema.europa.eu/en/documents/herbal-monograph/final-community-herbal-monograph-glycyrrhiza-glabra-l-andor-glycyrrhiza-inflata-bat-andor-glycyrrhiza-uralensis-fisch-radix-first-version_en.pdf
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.

    Do not use if you are taking heart medications, corticosteroids, stimulant laxatives, or other health products that may contribute electrolyte imbalance (Brinker 2010; ESCOP 2003; Hoffmann 2003; Blumenthal et al. 2000).

    Sources cited by Health Canada (4)
    • Blumenthal M, Goldberg A, Brinkmann J, editors. Herbal Medicine: Expanded Commission E Monographs. Boston (MA): Integrative Medicine Communications; 2000.
    • Brinker F. Herb Contraindications and Drug Interactions, 4th edition. Sandy (OR): Eclectic Medical Publications; 2010.
    • ESCOP 2003: ESCOP Monographs: The Scientific Foundation for Herbal Medicinal Products, 2nd edition. Exeter (UK): European Scientific Cooperative on Phytotherapy and Thieme; 2003.
    • Hoffmann D. Medical Herbalism. Rochester (VT): Healing Arts Press; 2003.

    Health Canada monograph dated 29 November 2024

They concern the ingredient, not this product or its dose. They do not replace medical advice.

Other declarations with the same name

In France, every company that markets a supplement declares it, so one product can have several declarations (new formula, another distributor, an older declaration withdrawn). Each line compares the declared composition with this page.

Is something on this product wrong or out of date, whether you are a reader or the brand? Write to contact@compoatlas.com: every correction is published in the corrections log.

Cite this page: CompoAtlas, “Pi pa qing fei yin: composition and regulation”, https://compoatlas.com/en/supplements/products/312671-pi-pa-qing-fei-yin, updated 15 November 2026.

List recorded in 2021. Photograph the packaging to check whether it has changed.

Enter to analyse, Shift+Enter for a new line